← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	151 PepGen PEPG $184M	–	–	–	–
152	152 Precigen PGEN $2.44B	–	–	–	–
153	153 PharmaCyte Biotech PMCB $3.82M	–	–	–	–
154	154 Prime Medicine PRME $633M	–	–	–	–
155	155 ProKidney PROK $280M	–	–	–	–
156	156 ProQR Therapeutics PRQR $198M	–	–	–	–
157	157 Personalis PSNL $1.69B	–	–	–	–
158	158 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
159	PTE 159 DELISTED PolarityTE, Inc. Common Stock PTE	–	–	–	–
160	160 Qiagen QGEN $9.51B	–	–	–	–
161	161 Quantum-Si Incorporated QSI $252M	–	–	–	–
162	162 uniQure QURE $1.53B	–	–	–	–
163	163 Ultragenyx Pharmaceutical RARE $1.46B	–	–	–	–
164	164 Rocket Pharmaceuticals RCKT $254M	–	–	–	–
165	RCOR 165 DELISTED Renovacor, Inc. RCOR	–	–	–	–
166	166 Regenxbio RGNX $465M	–	–	–	–
167	167 Atrium Therapeutics RNA $135M	–	–	–	–
168	168 Cartesian Therapeutics RNAC $197M	–	–	–	–
169	RUBY 169 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
170	170 Sana Biotechnology SANA $712M	–	–	–	–
171	SCPS 171 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
172	172 DELISTED Scorpius Holdings, Inc. SCPX	–	–	–	–
173	SCTX 173 Scribe Therapeutics Inc SCTX $378M	–	–	–	–
174	SGTX 174 DELISTED Sigilon Therapeutics, Inc. Common Stock SGTX	–	–	–	–
175	SIOX 175 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	–	–	–	–